May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Long– termI effects on IOP of a stainless steel glaucoma drainage implant (Ex–PRESS) in combined surgery with phacoemulsification.
Author Affiliations & Notes
  • F. De Feo
    DiNOG, Clinica Oculistica, Genoa, Italy
  • F. Badalà
    DiNOG, Clinica Oculistica, Genoa, Italy
  • S. Gandolfi
    Institute of ophthalmology, University of Parma, Parma, Italy
  • E. Sellem
    Center of Ophthalmology Kleber, Lyon, France
  • C.E. Traverso
    DiNOG, Clinica Oculistica, Genoa, Italy
  • Footnotes
    Commercial Relationships  F. De Feo, None; F. Badalà, None; S. Gandolfi, None; E. Sellem, None; C.E. Traverso, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 929. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. De Feo, F. Badalà, S. Gandolfi, E. Sellem, C.E. Traverso; Long– termI effects on IOP of a stainless steel glaucoma drainage implant (Ex–PRESS) in combined surgery with phacoemulsification. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):929.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate efficacy and safety in long term of a stainless steel miniature glaucoma drainage device (Ex–PRESS R50) for the surgical treatment of POAG and cataract, when combined with phacoemulsification . Methods: clinical, prospective, multicenter, single treatment arm, non randomized, non masked study. Phacoemulsification and in–the–bag IOL implantation were performed through clear cornea temporally. Primary outcome: IOP change. Secondary outcomes: side effects and VA changes. Results: 26 eyes of 25 patients were implanted with the device. The mean (±SD) follow–up was 23.9±10.4 months and the mean age was 74.8±6.7years. 17/26 eyes are beyond 3 years of F.U. One case was discontinued due to device removal, 1 due to death (not related to the device) and 3 were lost to follow up. Efficacy: preoperative IOP was 21±4 mmHg; at 1, 2 and 3 years IOP was 15.3±3.1mmHg (35% reduction), 16.6±2.7mmHg (29% reduction) and 16±2.6mmHg (22% reduction), respectively. Kaplan–Meyer determined overall success rate (IOP≤21mmHg at last visit with or without antiglaucoma medications) was 89%. The number of antiglaucoma medications was reduced by 95%, 86% and 100% at year 1, 2 and 3 respectively. Side effects: early postoperative complications were clinically mild and included 6 (23.1%) cases of hypotony (IOP≤5mmHg), 3 (11%) cases of hyphema <2mm with no clinical significant further effects. Long term complications were 2 (7.7%) cases of device rotation ( 1 treated by reposition) , 2 (7.7%) conjunctival erosions at 2 years. Conclusions:This technique is clinically safe and effective, maintaining in long term a large reduction of IOP and of the number of antiglaucoma medications.

Keywords: intraocular pressure • cataract 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.